Overview
Despite significant advances in screening technology, surgical technique, and systemic therapy, colon cancer management is characterized by a cascade of quantifiable gaps—from initial detection through curative-intent treatment to long-term surveillance. Synthesizing recent evidence from the United States, Europe, and China, this narrative identifies the most consequential practice deficits and their impact on clinical outcomes.
Screening Uptake, FIT-to-Colonoscopy Intervals, and Diagnostic Delays
Fecal immunochemical testing (FIT) serves as the primary population-level screening entry point in many health systems, yet the pathway from a positive FIT result to diagnostic colonoscopy remains a critical bottleneck. In a Chinese screening cohort of 246,349 invitees followed over a median 10.58 years, 61.1% participated in two-sample FIT screening; of 16,994 FIT-positive participants, only 75.4% underwent follow-up colonoscopy, representing a 24.6% FIT-to-colonoscopy compliance gap 5. Finland's inaugural national FIT-based screening round (2022–2023) demonstrated a similar 21% gap: of 1,407 FIT-positive individuals, only 79% attended colonoscopy 8. The clinical consequences of noncompliance are severe. Chinese data show that FIT-positive patients who did not undergo colonoscopy had a colorectal cancer incidence hazard ratio of 3.52 (95% CI 2.85–4.34) and a mortality hazard ratio of 4.41 (95% CI 2.96–6.55) relative to FIT-negative controls 5.
FIT threshold selection compounds detection performance. In a Norwegian trial of 47,265 participants, raising the FIT positivity threshold from 15 to 47 μg Hb/g feces would reduce colonoscopy volume by 49.3% but decrease colorectal cancer detection to 75.9% of original yield and halve advanced serrated lesion detection (50.0% retained). Stage I cancer detection rates fell from 0.22% to 0.11% at higher thresholds, indicating substantial stage migration toward later diagnoses 4.
Geographic distance exacerbates these delays independently. A National Cancer Database analysis of 356,189 patients found that increased distance from treating facilities was an independent predictor of advanced TNM stage at presentation (adjusted OR 1.12–1.62), added 5.06–14.46 days to time to surgery, and was associated with mortality hazard ratios of 1.11–1.28. Median overall survival decreased from 82.4 months for the nearest patient group to 75.1 months for the farthest 2.
In younger adults (ages 45–49 years), a randomized trial of 20,509 participants at UCLA Health revealed that default mailed FIT outreach achieved 26.2% participation—substantially higher than all active-choice intervention arms (14.5–17.4%), underscoring that system-level defaults outperform patient-directed choice in driving uptake 7.
Colonoscopy Quality Indicators
| Quality Measure | Compliance / Adherence | Key Gap |
|---|---|---|
| Cecal intubation rate | ≥90% of endoscopists meet targets 3 | Minimal gap in technical performance |
| Adenoma detection rate (ADR) | ≥90% meet performance targets 3 | Variation drives interval cancer risk |
| Follow-up for negative colonoscopy | 12.0% received ≤5-year interval (guideline: 10 years) 3 | Overuse of follow-up resources |
| Follow-up for 1–2 small tubular adenomas | 13.5% received ≤3-year interval (guideline: 5–10 years) 3 | Unnecessary over-surveillance |
| Follow-up for small sessile serrated polyps | 30.7% received ≤3-year interval (guideline: 5 years) 3 | High-frequency over-surveillance |
| Advanced serrated lesions | 18.2% received ≥5-year interval (guideline: 3 years) 3 | Under-surveillance of high-risk lesions |
Despite strong technical performance across the US endoscopy workforce, follow-up interval guideline nonadherence is prevalent, ranging from 12% to 30.7% depending on lesion type 3. This misallocation of endoscopy resources simultaneously over-surveils low-risk patients and under-monitors those at highest risk for interval cancer. Endoscopist ADR variation has direct outcome consequences: in the SCREESCO trial, first-round endoscopists with high ADR reduced second-round advanced colorectal neoplasia risk by 81–83% (aOR 0.17–0.19) compared with very-low-ADR endoscopists 6.
Undertreatment, Guideline Discordance, and Molecular Profiling Gaps
A national retrospective cohort of 222,583 US colon cancer patients (2018–2020) quantified treatment guideline adherence directly. Only 91.2% received guideline-concordant lymphadenectomy (≥12 lymph nodes examined for stages I–III) and 81.9% received guideline-concordant chemotherapy—meaning 8.8% of eligible patients had inadequate nodal harvest and 18.1% did not receive appropriate chemotherapy 1. Treatment at Commission on Cancer (CoC)-accredited hospitals was the strongest predictor of guideline-concordant care: adjusted OR 1.82 (95% CI 1.75–1.88) for lymphadenectomy and OR 2.14 (95% CI 2.06–2.23) for chemotherapy. Survival differentials were substantial across all stages:
In the adjuvant chemotherapy setting, a real-world British Columbia analysis of 452 stage III patients (2021–2022) revealed that despite five or more years of post-IDEA trial evidence supporting 3-month CAPOX equivalence, 48% of patients still received 6 months of therapy, with 29% of these being low-risk cases (pT1-3, pN0-1, well/moderately differentiated) 12. Early oxaliplatin discontinuation was significantly more common in the 6-month group (54% vs. 31%), driven by cumulative neuropathy (grade ≥2 neuropathy: 68% vs. 36%), and only 31% of patients who discontinued oxaliplatin early completed their fluoropyrimidine component 12.
Molecular profiling gaps represent a particularly high-stakes domain. A case report illustrates the consequence: an 81-year-old patient with metastatic disease initially classified as MSS by tissue testing was subsequently identified as MSI-H/dMMR with a BRAF V600E mutation via circulating tumor DNA testing, leading to complete clinical response with nivolumab addition after 8 months. Tissue NGS turnaround was 19 days versus 7 days for ctDNA, and the initial tissue biopsy missed the actionable metastatic biology entirely 11. This case reflects a broader gap: ctDNA testing remains underutilized for newly diagnosed metastatic CRC despite NCCN guideline recommendations for comprehensive biomarker assessment.
Body composition independently predicts adjuvant chemotherapy dose intensity: in 107 stage III patients receiving adjuvant FOLFOX, skeletal muscle index, age, and white blood cell count independently predicted relative dose intensity (RDI) achievement, yet standard dosing does not incorporate these parameters 14. A Sydney real-world analysis found that FOLFOX patients achieved higher RDI for fluoropyrimidine (85% vs. 78%) and oxaliplatin (72% vs. 66%) compared with CAPOX, yet CAPOX patients trended toward better 5-year DFS (84% vs. 78%, HR 0.53), particularly in high-risk cases (T4 or N2: 78% vs. 67%, HR 0.41, p = 0.042) 15.
Post-Treatment Surveillance: Adherence and ctDNA MRD Integration
A systematic review and meta-analysis of 14 studies (55,895 patients) quantified adherence to post-resection surveillance:
| Surveillance Modality | Overall Adherence | Gap vs. Colonoscopy |
|---|---|---|
| Colonoscopy | 70% (95% CI 67–73%) 25 | Reference |
| CT imaging | 63% (95% CI 47–80%) 25 | Lower |
| CEA testing | 54% (95% CI 42–66%) 25 | Significantly lower |
CEA adherence was significantly lower than colonoscopy among both colon (OR 0.21; 95% CI 0.20–0.22) and rectal cancer patients 25. This represents a critical missed opportunity for detecting resectable recurrences amenable to curative metastasectomy.
Circulating tumor DNA for MRD detection shows transformative potential but faces significant implementation barriers. A 2025 meta-analysis demonstrated that postoperative ctDNA positivity in stage II CRC increased recurrence risk with a pooled relative risk of 3.66 (95% CI 1.25–10.72) 20. A Korean prospective cohort study confirmed that postoperative MRD positivity at 3 weeks was associated with an adjusted HR of 8.40 (95% CI 3.49–20.2) for poor disease-free survival 22. The DYNAMIC trial demonstrated that ctDNA-guided adjuvant decisions reduced chemotherapy exposure without compromising 2-year recurrence-free survival. Despite this evidence, NCCN guidelines currently recommend against routine ctDNA-guided adjuvant therapy decisions outside clinical trials, with ACT3 and ALTAIR trials ongoing 21. Practical barriers include 8-week assay turnaround for tumor-informed panels 22, heterogeneity in detection methods, and absence of real-world equity data on access disparities 23.
Health Equity and Structural Disparities
Non-Hispanic Black patients are significantly less likely to receive guideline-concordant lymphadenectomy and chemotherapy, and this disparity persists after controlling for hospital type, socioeconomic status, and geographic location 1. CoC accreditation attenuated but did not eliminate these disparities, even among patients in nonmetropolitan locations or with low socioeconomic status 1. Patient navigation interventions—including telephone-based, nurse-led, and digitally tailored approaches (e.g., WeChat-based programs in China)—have demonstrated improvements in screening participation and reduction of social inequalities in access 21, though evidence on post-treatment surveillance equity barriers and ctDNA access disparities remains notably absent from recently retrieved literature.
Cost-Effectiveness and Adherence-Dependent Value
Modelling analysis comparing novel noninvasive tests highlights the dominant role of real-world adherence. Under perfect adherence, colonoscopy every 10 years is cost-effective (ICER US$261/QALY). Under realistic adherence assumptions, every-3-year multitarget stool RNA was the preferred cost-effective strategy (ICER US$95,250/QALY, highest probability of cost-effectiveness at 37.6% at a $100,000/QALY threshold) 9. This stark contrast demonstrates that adherence optimization can reorder the cost-effectiveness hierarchy of screening modalities entirely, and that technology selection without attention to real-world uptake may undermine screening program value.
Conclusion
The most impactful evidence-supported interventions include: (1) FIT-positive tracking and navigation systems to reduce the persistent ~21%–25% FIT-to-colonoscopy gap; (2) default mailed FIT outreach rather than active-choice strategies to improve screening participation, especially in adults aged 45–49 years; (3) care delivery through CoC-accredited, multidisciplinary programs, which is associated with a 2.14-fold increase in chemotherapy guideline concordance; (4) broader use of 3-month CAPOX for appropriate low-risk stage III colon cancer to reduce oxaliplatin-related neuropathy burden; (5) complementary tissue and ctDNA genomic profiling at metastatic diagnosis, where feasible, to improve detection of actionable biomarkers; and (6) structured CEA and imaging surveillance protocols to address persistent nonadherence after resection. These interventions should be linked to defined KPIs, including FIT-to-colonoscopy interval, ADR, dose intensity, and surveillance completion rates, and supported by informatics infrastructure to drive sustained improvements in stage distribution, survival, and equity.